Tumor Ploidy as a Risk Factor for Disease Recurrence and Short Survival in Surgically Treated Dukes’ B2 Colon Cancer Patients

Tumor Biology ◽  
1996 ◽  
Vol 17 (2) ◽  
pp. 75-80 ◽  
Author(s):  
Dattatreyudu Nori ◽  
Ofer Merimsky ◽  
Daisy Saw ◽  
Engracio Cortes ◽  
Ellen Chen ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Risk Factor ◽  
Cancer Patients ◽  
Disease Recurrence ◽  
Short Survival ◽  
Tumor Ploidy

Tumor ploidy as a risk factor for disease recurrence and short survival in surgically-treated dukes' B2 colon cancer patients

1995 ◽  
Vol 59 (4) ◽  
pp. 239-242 ◽  
Author(s):  
Dattatreyudu Nori ◽  
Ofer Merimsky ◽  
Engracio Samala ◽  
Daisy Saw ◽  
Engracio Cortes ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Risk Factor ◽  
Cancer Patients ◽  
Disease Recurrence ◽  
Short Survival ◽  
Tumor Ploidy

scholarly journals Risk factor for occlusion of central venous access port system in colon cancer patients

2013 ◽  
Vol 8 (1) ◽  
pp. 135-141
Author(s):  
Hisakazu Nishimori ◽  
Noriko Kouge ◽  
Hitomi Nishimoto ◽  
Yuko Tsuyumu ◽  
Yukie Matsushima ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Risk Factor ◽  
Cancer Patients ◽  
Central Venous Access ◽  
Venous Access ◽  
Central Venous ◽  
Access Port ◽  
Port System ◽  
Venous Access Port

Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence: Results of an accent meta-analysis of seven studies.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 3525-3525 ◽  
Author(s):  
Julien Taieb ◽  
Levi Pederson ◽  
Qian Shi ◽  
Steven R Alberts ◽  
Norman Wolmark ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cancer Patients ◽  
Mismatch Repair ◽  
Statistical Significance ◽  
Multivariable Analysis ◽  
Disease Recurrence ◽  
Stage Iii ◽  
Wild Type ◽  
Poor Prognostic Factor ◽  
Stage Iii Colon Cancer

3525 Background: Microsatellite instable/deficient mismatch repair (MSI) metastatic colorectal cancers have been reported to be of poor prognosis. The interaction between MSI and BRAFV600E mutation complicates the picture. Methods: Patients with resected stage III CC from 7 studies with disease recurrence and data available for MSI and BRAFV600E status were analyzed. The primary endpoint was survival after recurrence (SAR) to assess the prognostic roles of MSI and BRAFV600E, respectively. Associations of markers with SAR were analyzed using Cox proportional hazards models adjusted for clinicopathologic features (data collected 12/1998 to 11/2009). Results: Among 2630 patients with cancer recurrence (1491 men [56.7%], mean age, 58.5 [19-85] years), multivariable analysis revealed that patients with MSI tumors (n = 220) had significantly better SAR (adjusted hazard ratio [aHR], 0.82; 95% CI, 0.69-0.98; P = .029) than patients with microsatellite stable /proficient MMR (MSS) tumors (n = 1766). This was also observed when looking at patients treated by the standard FOLFOX adjuvant regimen only (aHR, 0.76; 0.58-1.00; P = .048). Same trends were observed when looking at MSI/dMMR patients outcome in BRAFV600E wild-type (aHR, 0.84; P = .10) and mutant (aHR, 0.88; P = .43) subgroups separately, without reaching statistical significance. As previously described poor SAR was observed in BRAFV600E mutants vs wild type patients (n = 244; aHR, 2.06; 95% CI, 1.73-2.46; P < .0001) and this was also true in BRAFV600E mutants MSI/dMMR patients (n = 77, aHR, 2.65 ; 95% CI, 1.67-4.21; p < .0001). Other factors associated with a poor SAR were : olderage, male gender, T4/N2, proximal primary tumor location, poorly differentiated adenocarcinoma, and early recurrence (by 1y increase). Conclusions: In stage III colon cancer patients recurring after adjuvant chemotherapy and before the era of immuno-oncologic agents, MSI/dMMR was associated with a better survival compared to MSS. BRAFV600E mutation seems to be a poor prognostic factor for both MSI/dMMR and MSS/pMMR patients.

P1571Atrial fibrillation is an independent predictor of mortality in hospitalized cancer patients

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
A H Malik ◽  
S Shetty ◽  
S Malik
Keyword(s):  
Atrial Fibrillation ◽  
Colon Cancer ◽  
Risk Factor ◽  
Hospital Mortality ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Independent Risk Factor ◽  
Attributable Mortality ◽  
Patients With Cancer ◽  
Hospitalised Patients

Abstract Background Atrial fibrillation (AF) is prevalent in patients with cancer. We performed a study to evaluate the outcomes associated with hospitalised cancer patients with AF. Methods The Nationwide Inpatient Sample was used to identify patients with a cancer diagnosis, who were found to have atrial fibrillation from the years 2002–2014. Descriptive statistics for mortality were calculated using univariate and multivariate model for each cancer, and we identified the type of cancer associated with the highest inpatient mortality. We also calculated the percentage of hospital mortality attributable to AF. Results 12,410,290 (nationwide estimate) patients with a cancer diagnosis were identified, and 8.2% of them had AF. In a multivariate adjusted model for various relevant comorbidities, age, gender and race, AF was also found to be an independent risk factor for higher in-hospital mortality in cancer patients, odds ratio (OR) 1.25 (95% CI 1.23, 1.28, p<0.0001). Colon cancer was found to be associated with the worst outcomes and the highest mortality. In cancer patients, the incident percentage of hospital mortality attributed to AF was 46.7%, population attributable mortality risk of was 7.17%, and number needed to harm was 21 (p<0.0001). Conclusion AF conferred significant morbidity and was found to be an independent risk factor for increased mortality in hospitalised patients with cancer. Colon cancer was found to have the strongest association of worst outcomes in hospitalized patients with AF. Acknowledgement/Funding None

scholarly journals Long-Term Outcomes of Colon Cancer Patients Undergoing Standardized Technique Operation With Curative Intent

2015 ◽  
Vol 100 (11-12) ◽  
pp. 1382-1395
Author(s):  
Erhan Akgun ◽  
Cemil Caliskan ◽  
Tayfun Yoldas ◽  
Can Karaca ◽  
Bulent Karabulut ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cancer Patients ◽  
Cox Regression ◽  
Disease Free Survival ◽  
Disease Recurrence ◽  
R0 Resection ◽  
Cancer Specific Survival ◽  
Curative Intent ◽  
Lymph Node Count

There is no defined standard surgical technique accepted worldwide for colon cancer, especially on the extent of resection and lymphadenectomy, resulting in technical variations among surgeons. Nearly all analyses employ more than one surgeon, thus giving heterogeneous results on surgical treatment. This study aims to evaluate long-term follow-up results of colon cancer patients who were operated on by a single senior colorectal surgeon using a standardized technique with curative intent, and to compare these results with the literature. A total of 269 consecutive patients who were operated on with standardized technique between January 2003 and June 2013 were enrolled in this study. Standardized technique means separation of the mesocolic fascia from the parietal plane with sharp dissection and ligation of the supplying vessels closely to their roots. Patients were assessed in terms of postoperative morbidity, mortality, disease recurrence, and survival. Operations were carried out with a 99.3% R0 resection rate and mean lymph node count of 17.7 nodes per patient. Surviving patients were followed up for a mean period of 57.8 months, and a total of 19.7% disease recurrence was recorded. Mean survival was 113.9 months. The 5- and 10-year survival rates were 78% and 75.8% for disease-free survival, 82.6% and 72.9% for overall survival, and 87.5% and 82.9% for cancer-specific survival, respectively. R1 resection and pathologic characteristics of the tumor were found to be the most important prognostic factors according to univariate and Cox regression analyses. Standardization of surgical therapy and a dedicated team are thought to make significant contributions to the improvement of prognosis.

Recurrence risk factors and outcome stratification in stage II colon cancer patients: A subanalysis of the SACURA trial.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 3611-3611
Author(s):  
Megumi Ishiguro ◽  
Eiji Nakatani ◽  
Hideki Ueno ◽  
Toshiaki Ishikawa ◽  
Hiroyuki Uetake ◽  
...  
Keyword(s):  
Risk Factors ◽  
Colon Cancer ◽  
Risk Factor ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Recurrence Rate ◽  
Clinicopathological Characteristics ◽  
Stage Ii ◽  
Risk Factors For Recurrence ◽  
Stage Ii Colon Cancer

3611 Background: Efficacy of adjuvant chemotherapy for stage II colon cancer is still controversial. We conducted the SACURA trial, a phase III study which evaluated the superiority of 1-year adjuvant treatment with oral tegafur-uracil (UFT) to surgery alone in stage II colon cancer. However, survival benefit of 1-year UFT to surgery alone was not demonstrated (ASCO2016 abst#3617). We herein aimed to identify risk factors for recurrence in the stage II patients “without adjuvant chemotherapy”, and to stratify the prognosis by using these factors. Methods: Among a total of 982 patients without adjuvant chemotherapy enrolled to the SACURA trial, we extracted the factors correlated to recurrence using a univariate and multivariate Cox proportional hazard model. 943 and 935 patients in the surgery alone group and UFT group were divided to subgroups according to the number of risk factors, and the recurrence rate in each subgroup was evaluated. Results: Among the conventional clinicopathological characteristics, the multivariate analysis identified pT4, elevated CEA, and examined lymph nodes less than 12 as significant risk factors for recurrence. The rate of patients with 0, 1, 2, and 3 risk factors were 45.0%, 42.4%, 11.5%, and 1.1%, respectively. The recurrence rate for each subgroup was shown in the table: the recurrence rate increased with number of risk factors, while 10.2% of patients without any risk factors developed recurrence. Difference in the recurrence rate between the treatment groups was significant in patients without risk factor, marginal in patients with 1 risk factor, and none in patients with >1 factors. Conclusions: pT4, elevated CEA, and examined lymph nodes less than 12 were identified as risk factors for recurrence in stage II colon cancer patients. The recurrence rate was divided by the number of these risk factors, but we could not extract the very-low risk group in whom adjuvant therapy is unnecessary. Induction of novel risk factors other than conventional clinicopathological characteristics is recommended. Clinical trial information: NCT00392899. [Table: see text]

Investigation of Thymidylate synthase gene polymorphism in colon cancer patients

2012 ◽  
Vol 50 (05) ◽  
Author(s):  
A Schöller ◽  
A Kalmár ◽  
VÁ Patai ◽  
Z Nagy ◽  
B Barták ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Gene Polymorphism ◽  
Cancer Patients ◽  
Thymidylate Synthase
Sign in / Sign up

Export Citation Format

Share Document